Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 209 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Down Syndrome (Trisomy 21) Clear all
Completed Phase 1Phase 2 Interventional Results available

Rivastigmine Study in Adolescents With Down Syndrome

NCT01084135
View directory record Official record
Conditions
Down Syndrome
Interventions
Rivastigmine, Liquid Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced Jun 10, 2026, 2:08 PM EDT
Completed No phase listed Observational

Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

NCT01555346
View directory record Official record
Conditions
Down Syndrome, Fetal Aneuploidy
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Mobile, Alabama • Tucson, Arizona • Campbell, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Jun 10, 2026, 2:08 PM EDT
Not listed Not applicable Interventional

Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome

NCT04668001
View directory record Official record
Conditions
Down Syndrome
Interventions
Near-Infrared Transcranial Photobiomodulation, Sham Transcranial Photobiomodulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Jun 10, 2026, 2:08 PM EDT
Completed No phase listed Observational

Healthy Sleep for Children With Down Syndrome

NCT03922165
View directory record Official record
Conditions
Down Syndrome, Sleep Disordered Breathing
Interventions
Adenotonsillectomy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
3 Years to 13 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jun 10, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multiple Gestation Study

NCT02278536
View directory record Official record
Conditions
Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
6
States / cities
San Carlos, California • San Diego, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome

NCT01112683
View directory record Official record
Conditions
Down Syndrome
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 32 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jun 10, 2026, 2:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

NCT04726241
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions
Biospecimen Collection
Procedure
Lead sponsor
PedAL BCU, LLC
Other
Eligibility
Up to 22 Years
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
164
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

A Study of RG1662 in Individuals With Down Syndrome

NCT01436955
View directory record Official record
Conditions
Down Syndrome
Interventions
Placebo, RG1662
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome

NCT02421276
View directory record Official record
Conditions
Down Syndrome, Polyendocrinopathies, Autoimmune, Respiratory Tract Infections, Autoimmunity
Interventions
Phlebotomy
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 22 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model

NCT01148121
View directory record Official record
Conditions
Down Syndrome
Interventions
Skeletal Status Assessment of a Down Syndrome Population
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jun 10, 2026, 2:08 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

NCT00754013
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (Donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jun 10, 2026, 2:08 PM EDT
Not listed No phase listed Observational

Non-Invasive Screening for Fetal Aneuploidy

NCT02317965
View directory record Official record
Conditions
Down Syndrome, Edwards Syndrome
Interventions
Maternal Blood Draw
Other
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years to 54 Years · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Campbell, California • Long Beach, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Jun 10, 2026, 2:08 PM EDT
Completed No phase listed Observational

A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)

NCT01920633
View directory record Official record
Conditions
Down Syndrome
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 30 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
La Jolla, California • Decatur, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jun 10, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

NCT06673069
View directory record Official record
Conditions
Alzheimer Disease, Down Syndrome
Interventions
ION269
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
35 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Indianapolis, Indiana • Kansas City, Kansas • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Proactive Speech and Language Intervention for Infants With Down Syndrome

NCT06450509
View directory record Official record
Conditions
Down Syndrome
Interventions
Babble Boot Camp
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
0 Months to 12 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

NCT02381457
View directory record Official record
Conditions
22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Sex Chromosome Abnormalities, Cri-du-Chat Syndrome, Angelman Syndrome, Prader-Willi Syndrome, 1p36 Deletion Syndrome
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
20,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
16
States / cities
San Francisco, California • Camden, New Jersey • Mount Laurel, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jun 10, 2026, 2:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Vascular Function in Adults With Down Syndrome

NCT07630207
View directory record Official record
Conditions
Down Syndrome (Trisomy 21)
Interventions
Not listed
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Recruiting Not applicable Interventional

Adapting RDAD for DS

NCT07425769
View directory record Official record
Conditions
Down Syndrome (DS), Alzheimer's Disease (AD)
Interventions
Remote Exercise Sessions, Caregiver Education Sessions
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Investigating the Experience of Living With Down Syndrome and Obstructive Sleep Apnea Syndrome (Stage 1)

NCT04124471
View directory record Official record
Conditions
Down Syndrome, Obstructive Sleep Apnea
Interventions
Open-ended semi-structured interviews
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome

NCT01808508
View directory record Official record
Conditions
Down Syndrome, Obstructive Sleep Apnea Syndrome
Interventions
Continuous positive airway pressure, Sham or placebo continuous positive airway pressure
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 20 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

NCT00928304
View directory record Official record
Conditions
Down Syndrome, Amyloid Beta-protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
21 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Sun City, Arizona • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Decision Assisting Tool for Prenatal Testing

NCT00686062
View directory record Official record
Conditions
Pregnancy
Interventions
Control - computerized age-appropriate prenatal testing educational brochure, PT Tool - interactive, computerized, prenatal testing decision tool
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

NCT00003593
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Jun 10, 2026, 2:08 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study

NCT02612376
View directory record Official record
Conditions
Alzheimer Disease, Down Syndrome, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jun 10, 2026, 2:08 PM EDT